More than 8 million people in Europe and the US suffer from moderate to severe mitral valve regurgitation (blood leaking back into the heart´s left atrium). If left untreated, this condition may ultimately lead to heart failure. Open-heart surgery is the current gold-standard for treating mitral valve prolapse. Due to significant procedure risks for the patients, up to 50% of the affected population are left untreated. The Mitral Butterfly implant is based on a unique physiological design that can be deployed in one-step. Transcatheter implantation provides for a minimally invasive procedure.
More than 8 million people in Europe and the US suffer from moderate to severe mitral valve regurgitation (blood leaking back into the heart´s left atrium). If left untreated, this condition may ultimately lead to heart failure. Open-heart surgery is the current gold-standard for treating mitral valve prolapse. Due to significant procedure risks for the patients, up to 50% of the affected population are left untreated. The Mitral Butterfly implant is based on a unique physiological design that can be deployed in one-step. Transcatheter implantation provides for a minimally invasive procedure.
Company Information
- Industry
- Medical Devices
- Company Type
- Privately Held
- Founded
- unknown
- Employee Range
- 11-50
- Revenue Range
- Not available
Location
- Address
- Vienna Vienna
- City
- Vienna
- Region
- Wien
- Postal Code
- 1090
- Country
- Austria